All In Biotech

Drug Trial Radar · NCT07284043

A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Nov 27, 2025

Primary completion

May 14, 2026

Study completion May 14, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] MT1013.

Conditions

  • Hemodialysis Subjects With Secondary Hyperparathyroidism

Interventions

  • [14C] MT1013/MT1013 InjectionDrug

    \[14C\] MT1013/MT1013 Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative excretion of radioactivityTime frame: Day 1 to Day 91.
  2. Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)Time frame: Day 1 to Day 91.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.